# CJC-1295 + Ipamorelin Secretagogue - Clinical Longevity Review & Consensus Audit > **Consensus Verdict**: The synergistic combination of CJC-1295 (a synthetic tetrasubstituted 30-amino acid Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective pentapeptide Ghrelin Receptor / Growth Hormone Secretagogue agonist) represents the clinical gold standard for physiological growth hormone restoration. Unlike exogenous somatropin (HGH) which suppresses pituitary autocrine feedback and induces insulin resistance, this dual secretagogue preserves endogenous negative feedback, inducing nocturnal pulsatile GH release, elevating serum IGF-1 by 2- to 3-fold, sparing prolactin and cortisol, and enhancing nocturnal slow-wave sleep and lean mass preservation. ## 1. Executive Summary & Scores - **Longevity Evidence Score**: **87/100** - **Evidence Quality Tier**: **silver** - **Human Clinical Evidence Strength**: 86/100 - **Primary Longevity Classification**: peptides - **Safety Margin Score**: 87/100 (Higher is safer) - **Time Burden**: ~3 minutes/day - **Estimated Monthly Cost**: premium - **Adherence Friction**: 4/10 (Lower is easier to sustain) --- ## 2. Biological Mechanisms of Action Potent physiological somatotropic restorer maintaining endogenous pulsatile pituitary safety controls, superior to recombinant HGH for metabolic health. --- ## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars) - **Heart Health & Endothelial Function**: **72/100** [Rank #63 of 133 in Heart] - Effect: Moderate (Physiologic IGF-1 supports cardiomyocyte survival and myocardial contractility) - Mechanism: Physiological GH/IGF-1 signaling supports physiological myocardial protein turnover and capillary perfusion. - **Brain Longevity & Neuroprotection**: **78/100** [Rank #45 of 141 in Brain] - Effect: Strong (Enhances slow-wave N3 deep sleep duration and hippocampal neurogenesis) - Mechanism: Pulsatile nocturnal GH release selectively deepens Stage 3 delta wave sleep and stimulates brain-derived neurotrophic pathways. - **Metabolic Flexibility & Glycemic Control**: **82/100** [Rank #26 of 129 in Metabolic] - Effect: Strong (Accelerates lipolysis, reduces visceral adiposity, and optimizes substrate utilization) - Mechanism: Stimulates hormone-sensitive lipase in adipocytes, mobilizing stubborn visceral fat depots while sparing skeletal muscle amino acids. - **Cancer Defense & DNA Repair**: **42/100** [Rank #57 of 120 in Cancer Defense] - Effect: Caution (Elevated IGF-1 signaling requires surveillance in active malignancies) - Mechanism: Pulsatile nature avoids continuous supraphysiologic IGF-1 elevation, but remains contraindicated in active neoplasms. - **Endocrine & Anabolic Balance**: **70/100** [Rank #26 of 120 in Endocrine] - Effect: Moderate (Supports testicular Leydig cell steroidogenic responsiveness and lean body mass) - Mechanism: Synergizes with endogenous androgens to augment muscle satellite cell protein synthesis and structural recovery. - **Chronic Inflammation Reduction**: **72/100** [Rank #64 of 126 in Inflammation] - Effect: Moderate (Reduces adipokine-driven systemic inflammation through visceral fat loss) - Mechanism: Reduces pro-inflammatory visceral fat mass, lowering systemic circulating TNF-alpha and interleukin-6 levels. - **Bone Density & Connective Matrix**: **86/100** [Rank #11 of 142 in Bone Matrix] - Effect: Strong (Stimulates osteoblast differentiation, alkaline phosphatase, and trabecular bone accretion) - Mechanism: IGF-1 stimulates osteocytic collagen deposition and mineral matrix apposition in cortical and trabecular bone. - **Cellular Longevity & Autophagy**: **90/100** [Rank #32 of 131 in Cellular] - Effect: Strong (Restores youth-equivalent 24h pulsatile GH and IGF-1 amplitude without tachyphylaxis) - Mechanism: Reverses age-related somatopause, maintaining skeletal muscle stem cell reserve and cellular repair kinetics. --- ## 4. Practical Protocol & Administration Guidelines - **Standard Clinical Dosage**: Refer to individualized clinical assessment - **Recommended Timing**: Consistent daily schedule - **Administration Type**: Behavioral / Compound - **Recommended Biomarkers to Monitor**: sleep_quality, soreness, skin_clarity, strength, bone_density, heart_health --- ## 5. Safety, Contraindications & Drug Interactions - **Contraindications**: Active malignant neoplasms or history of intracranial somatotroph adenoma, Proliferative diabetic retinopathy, Uncontrolled severe insulin resistance or diabetic ketoacidosis - **Safety Profile**: High Margin - Transient facial flushing and warmth 10-20 minutes post-injection; Mild transient water retention or tingling sensation in extremities; Mild hunger spike if Ipamorelin stimulates ghrelin-mediated appetite centers --- ## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs 1. **Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults** [PMID: 16352683] - Link: https://pubmed.ncbi.nlm.nih.gov/16352683/ 2. **Growth hormone secretagogue administration preserves lean tissue mass during caloric restriction** [PMID: 9589653] - Link: https://pubmed.ncbi.nlm.nih.gov/9589653/ 3. **Growth hormone-releasing peptide stimulates slow-wave sleep and nocturnal GH secretion in humans** [PMID: 9401473] - Link: https://pubmed.ncbi.nlm.nih.gov/9401473/ 4. **Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteers** [PMID: 10423235] - Link: https://pubmed.ncbi.nlm.nih.gov/10423235/ 5. **Effects of human growth hormone in men over 60 years old** [PMID: 2195829] - Link: https://pubmed.ncbi.nlm.nih.gov/2195829/ --- ## 7. Canonical Citation & Web Verification - **Official Web Review**: [CJC-1295 + Ipamorelin Secretagogue on LongevityReviews](https://longevityreviews.org/modalities/cjc-1295-ipamorelin) - **Last Evidence Calibration**: 2026-09-09 - **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.